Existing antibody molecules are converted in proprietary AbAccel® libraries and screened for variants with optimized affinities and biophysical properties
Proprietary AbAccel® libraries are cloned for existing lead candidates and screened for variants with optimized affinities and biophysical properties. AbAccel® has identified optimized antibody candidates that demonstrated a more than 100-fold improved affinity, while preserving other properties such as species cross-reactivity, specificity and stability. Lead optimization with AbAccel® is based on a proprietary algorithm. HCDR3 regions of lead candidates are identified and transferred to a compatible VH/VL framework pair with proven performance for GMP production.